Abstract

BackgroundPatients with type 2 diabetes (T2D) face a high amputation rate. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating biomarkers, Tumor Necrosis Factor Receptor 1 (TNFR1) and Angiopoietin like-2 protein (ANGPTL2).MethodsWe have analyzed data from 1468 T2D participants in a single center prospective cohort (the SURDIAGENE cohort). Our outcome was the occurrence of lower limb amputation categorized in minor (below-ankle) or major (above ankle) amputation. Microvascular disease was defined as a history of albuminuria [microalbuminuria: uACR (urinary albumine-to-creatinine ratio) 30–299 mg/g or macroalbuminuria: uACR ≥ 300 mg/g] and/or severe diabetic retinopathy or macular edema. Macrovascular disease at baseline was divided into peripheral arterial disease (PAD): peripheral artery revascularization and/or major amputation and in non-peripheral macrovascular disease: coronary artery revascularization, myocardial infarction, carotid artery revascularization, stroke. We used a proportional hazard model considering survival without minor or major amputation.ResultsDuring a median follow-up period of 7 (0.5) years, 79 patients (5.5%) underwent amputation including 29 minor and 50 major amputations. History of PAD (HR 4.37 95% CI [2.11–9.07]; p < 0.001), severe diabetic retinopathy (2.69 [1.31–5.57]; p = 0.0073), male gender (10.12 [2.41–42.56]; p = 0.0016) and serum ANGPTL2 concentrations (1.25 [1.08–1.45]; p = 0.0025) were associated with minor amputation outcome. History of PAD (6.91 [3.75–12.72]; p < 0.0001), systolic blood pressure (1.02 [1.00–1.03]; p = 0.004), male gender (3.81 [1.67–8.71]; p = 0.002), and serum TNFR1 concentrations (HR 13.68 [5.57–33.59]; p < 0.0001) were associated with major amputation outcome. Urinary albumin excretion was not significantly associated with the risk of minor and major amputation.ConclusionsThis study suggests that the risk factors associated with the minor vs. major amputation including biomarkers such as TNFR1 should be considered differently in patients with T2D.

Highlights

  • Cardiovascular disease constitutes the major determinant of mortality and morbidity in patients with type 2 diabetes (T2D) [1]

  • Peripheral arterial disease (PAD) is a common and severe clinical manifestation of atherosclerosis [2, 3] and is especially frequent in patients with T2D, with a threefold increased risk compared with a population without diabetes [4]

  • Men had no significant difference of Angiopoietin like-2 protein (ANGPTL2) concentrations (15.5 [6.5–24.5] ng/ ml vs. 15.0 [5.0–25.0] ng/ml, respectively; p = 0.243), and no significant difference of Tumor Necrosis Factor Receptor 1 (TNFR1) concentrations (1866.00 [1126.75–2605.25] pg/ml vs. 1853.00 [970.5– 2735.50] pg/ml, respectively; p = 0.262)

Read more

Summary

Introduction

Cardiovascular disease constitutes the major determinant of mortality and morbidity in patients with type 2 diabetes (T2D) [1]. PAD is associated with poor outcomes, leading to a high rate of amputation and death [5], and with an increased risk of cardiovascular morbidity and mortality [6]. As PAD affects mainly the infra-popliteal arteries and may induce more damage in small than in large vessels in T2D patients [12], micro- or macro-vascular disease could be differently associated with the level of lower limb amputation. This question remains largely unaddressed in the literature. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating bio‐ markers, Tumor Necrosis Factor Receptor 1 (TNFR1) and Angiopoietin like-2 protein (ANGPTL2)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call